Defining antibiotic dosing in lung infections

Clinical Pulmonary Medicine

Volumn 20, Issue 3, 2013, Pages 121-128

  Jamal, Janattul Ain ^a   Abdul Aziz, Mohd Hafiz ^a   Lipman, Jeffrey ^a,b   Roberts, Jason A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Pharmacodynamics; Pharmacokinetics; PK PD; Pulmonary; Therapeutic drug monitoring

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTAZIDIME; COLISTIN; ERTAPENEM; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PIPERACILLIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; LUNG INFECTION; LUNG PARENCHYMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEBULIZATION; PERSONALIZED MEDICINE; PHYSICAL CHEMISTRY; PROBABILITY; RENAL REPLACEMENT THERAPY; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 84877706649     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0b013e31828fc646     Document Type: Article

References (50)

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323-2329.
2. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis. 2002;35:228-235. (Pubitemid 34800268)
3. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004; 164:637-644. (Pubitemid 38392978)
4. Cazzola M, Blasi F, Terzano C, et al. Delivering antibacterials to the lungs: Considerations for optimizing outcomes. Am J Respir Med. 2002;1:261-272. (Pubitemid 37038945)
5. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameter. 2012; version 2.0. Available at: Http://www.eucast.org. Accessed October 13, 2012.
6. Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol. 2011;12: 2070-2079.
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.
8. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17:479-501. (Pubitemid 38029149)
9. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345-351.
10. Roberts JA, Paratz JD, Paratz ED, et al. Continuous infusion of time-dependent antibiotics: Lung pharmacokinetics and pharmacodynamics. Clin Pulm Med. 2008;15:167-172. (Pubitemid 351775232)
11. Conte JE Jr, Golden JA, McIver M, et al. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int J Antimicrob Agents. 2007;30:422-427. (Pubitemid 47500200)
12. Noreddin AM, Marras TK, Sanders K, et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents. 2004;24:479-484. (Pubitemid 39425161)
13. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest. 2004;125:965-973. (Pubitemid 38367287)
14. Nicolau DP, Sutherland C, Winget D, et al. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther. 2012;25:94-98.
15. Conte JE Jr., Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25:523-529. (Pubitemid 40732607)
16. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005;33:1529-1533. (Pubitemid 40980608)
17. Boselli E, Breilh D, Djabarouti S, et al. Reliability of minibronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med. 2007;33:1519-1523. (Pubitemid 47312468)
18. Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005;128:545-552. (Pubitemid 41140478)
19. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993;37:281-286. (Pubitemid 23046569)
20. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012;56:2627-2634.
21. Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med. 2006;32:775-779.
22. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2012;52: 1-8.
23. Boselli E, Breilh D, Cannesson M, et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30:976-979. (Pubitemid 38639495)
24. Boselli E, Breilh D, Rimmele T, et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med. 2008;36:1500-1506. (Pubitemid 351620671)
25. Boselli E, Breilh D, Rimmele T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30:989-991. (Pubitemid 38639498)
26. Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003;31:2102-2106. (Pubitemid 37011688)
27. Conte JE Jr., Golden JA, Kelley MG, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents. 2005;26:449-456. (Pubitemid 41635494)
28. Boselli E, Breilh D, Saux MC, et al. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med. 2006;32:2059-2062. (Pubitemid 44833122)
29. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother. 2003;47:2450-2457. (Pubitemid 36919444)
30. Zhang J, Xie X, Zhou X, et al. Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. J Clin Pharmacol. 2010;50: 922-928.
31. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med. 2005;33:104-109. (Pubitemid 40116543)
32. Georges H, Leroy O, Alfandari S, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis. 1997;16:385-388. (Pubitemid 27271829)
33. Lodise TP, Drusano GL, Butterfield JM, et al. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother. 2011;55:5507-5511.
34. Boselli E, Breilh D, Caillault-Sergent A, et al. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2012;67:1207-1210.
35. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010; 138:1333-1339.
36. Markou N, Fousteri M, Markantonis SL, et al. Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium. Chest. 2011;139:232-233, author reply 233-234.
37. Lodise TP, Kinzig-Schippers M, Drusano GL, et al. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrob Agents Chemother. 2008;52:1945-1951. (Pubitemid 351758528)
38. Mazzei T, Novelli A, Esposito S, et al. New insight into the clinical pharmacokinetics of cefaclor: Tissue penetration. J Chemother. 2000;12:53-62. (Pubitemid 30139829)
39. Lodise TP, Sorgel F, Melnick D, et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2011;55:1606-1610.
40. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter doubleblind, randomized controlled trial. Clin Infect Dis. 2013;56: 236-244.
41. Abdul-Aziz MH, Dulhunty JM, Bellomo R, et al. Continuous betalactam infusion in critically ill patients: The clinical evidence. Ann Intensive Care. 2012;2:37.
42. Kikuchi J, Yamazaki K, Kikuchi E, et al. Pharmacokinetics of telithromycin using bronchoscopic microsampling after single and multiple oral doses. Pulm Pharmacol Ther. 2007; 20:549-555. (Pubitemid 47077646)
43. RybakM, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
44. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin Infect Dis. 2012;54:621-629.
45. Athanassa ZE, Markantonis SL, Fousteri MZ, et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012; 38:1779-1786.
46. Luyt CE, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13:R200.
47. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial beta-lactam concentrations in select critically ill patients: Association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142:30-39.
48. Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: A multicentre pharmacokinetic study. Crit Care Med. 2012;40:1523-1528.
49. Roberts JA, Lipman J. Antibacterial dosing in intensive care: Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45:755-773.
50. Jamal JA, Economou CJ, Lipman J, et al. Improving antibiotic dosing in special situations in the ICU: Burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care. 2012;18:460-471.